Back to homepage

Health Economics & Outcomes Research

Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia

Authors: Michele Wilson, Benjamin Gutierrez, Steve J Offord, Christopher M Blanchette, Anna Eramo, Stephanie Earnshaw, Siddhesh A Kamat

Schizophrenia is associated with high direct healthcare costs due to progression of disease and frequent occurrence of relapses. Aripiprazole once-monthly (AOM) has been shown to reduce total psychiatric hospitalizations among patients who switched from oral standard of care (SOC) therapy to AOM. In this paper the authors report the results of an economic model study to evaluate the psychiatric hospitalization-related medical costs and antipsychotic pharmacy costs during a 6-month period before and after initiation of AOM treatment.

More

An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries

Authors: Marco Turini, Vittoria Piovesana, Pierfrancesco Ruffo, Claudio Ripellino, Nazarena Cataldo

Inadequately treated, chemotherapy-induced nausea and vomiting (CINV) can lead to increased resource utilization and severely impair patients’ daily functioning and quality of life. The authors investigated the management of CINV episodes in three European health-care environments and estimate the direct costs associated with severe CINV episodes.

More

Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease

Authors: Christopher M Blanchette, Caihua Liang, Deborah P Lubeck, Britt Newsome, Sandro Rossetti, Xiangmei Gu, Benjamin Gutierrez, Nancy D Lin

Autosomal dominant polycystic kidney disease (ADPKD) is a progressive genetic disorder characterized by the development of numerous kidney cysts that result in kidney failure. The results of this study suggest that distribution of patients by age at transition to next stage may be useful for identification of ADPKD patients at risk of rapid progression.

More

Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients

Authors: Siddhesh A Kamat, Steve Offord, John Docherty, Jay Lin, Anna Eramo, Ross A Baker, Benjamin Gutierrez, Craig Karson

The results from this large cohort study provided naturalistic real-world evidence of the utility of LAIs in patients with schizophrenia and suggest that these agents may help to reduce the risk of relapse across all age groups, especially among younger patients.

More

Cachexia & debility diagnoses in hospitalized children and adolescents with complex chronic conditions: evidence from the Kids’ Inpatient Database

Authors: Bryce A Van Doren, Debosree Roy, Joshua M Noone, Christopher M Blanchette, Susan T Arthur

In this original research article, the authors aimed to characterize the frequency, cost, and hospital reported outcomes of cachexia and debility in children and adolescents with complex chronic conditions (CCCs).

More